Back to results
R21/Matrix-M Vaccine for Malaria
Malaria presents one of the biggest global health problems, and remains to be one of the most common diseases in Africa, resulting in over 400,000 deaths per year. The new R21/Matrix-M vaccine developed by Oxford University in collaboration with Novavax has reported 77% efficacy in African Children - an amazing result with the potential to save thousands of lives. The following learning objectives will be addressed in this course:
- Malaria infection cycle
- Signs and symptoms
- World Health Organisation targets & strategy
- Malaria vaccine
- How the vaccine works